Janiel M. Cragun

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Pharmacology, Pathology +6

Genomic signatures to guide the use of chemotherapeutics

Anil Potti, Holly K. Dressman, Andrea Bild et al. · Nature Medicine · 2006 · 593 citations

Genomic Signatures, Biomolecular Tool, Tumor Heterogeneity +6

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

Janiel M. Cragun, Laura J. Havrilesky, Brian Calingaert et al. · Journal of Clinical Oncology · 2005 · 444 citations

An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer

Holly K. Dressman, Andrew Berchuck, Gina Chan et al. · Journal of Clinical Oncology · 2007 · 280 citations · Full text

Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology

Christopher V. Lutman, Laura J. Havrilesky, Janiel M. Cragun et al. · Gynecologic Oncology · 2006 · 205 citations

Tumoral Pathology, Endocrine-related Cancer, Ii Endometrial Carcinoma +10